title: Interleukin-2 activates human peripheral blood eosinophils.
abstract: The effect of interleukin (IL)-2 on eosinophil survival and mediator release was investigated in vitro. Human peripheral blood eosinophils were isolated and purified from mildly atopic donors and cultured on albumin-coated wells with different concentrations of IL-2, interferon (IFN)-gamma, and granulocyte-macrophage colony stimulating factor (GM-CSF) and their viability was evaluated after 4 days in culture. Eosinophils were cultured with IL-2 (1000 u/ml), IFN-gamma (1000 u/ml), or GM-CSF (10 ng/ml) for 18 h, or with platelet activating factor (PAF) (10(-6) M) for 20 min, and the release of eosinophil peroxidase (EPO) and IL-6 was measured. Nedocromil sodium (10(-5) M) was added with each of the above cytokines to study the inhibitory effect of this drug on EPO release. A significant increase of EPO release was induced by IL-2, IFN-gamma, and GM-CSF after 18 h in culture. IL-2 as well as IFN-gamma induced a significant IL-6 release from eosinophils. Nedocromil sodium significantly inhibited EPO release from eosinophils induced by IL-2 or PAF. These results show that IL-2 can activate peripheral blood eosinophils to release granule mediators (EPO) and cytokines (IL-6). Taken together with the presence of IL-2 receptors on eosinophils, we conclude that IL-2 is an important mediator in allergic inflammation and a possible target for pharmacological modulation.
authors.affiliation: Department of Pharmacology, Hadassah University Hospital and The Hebrew University, Jerusalem, 91120, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Hoenstein
authors.forename: D
authors.initials: D
authors.lastname: Admon
authors.forename: A
authors.initials: A
authors.lastname: Solomon
authors.forename: A
authors.initials: A
authors.lastname: Norris
authors.forename: R
authors.initials: R
authors.lastname: Moqbel
authors.forename: F
authors.initials: F
authors.lastname: Levi-Schaffer
mesh_terms: D018926:Anti-Allergic Agents / Q000494:pharmacology; D002478:Cells, Cultured; D003594:Cytoplasmic Granules / Q000378:metabolism; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000473:pathology; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000378:metabolism; D017835:Nedocromil / Q000494:pharmacology; D010544:Peroxidases / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology; D013268:Stimulation, Chemical
chemical_list: D018926:Anti-Allergic Agents; D007376:Interleukin-2; D015850:Interleukin-6; D010972:Platelet Activating Factor; D017835:Nedocromil; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D047209:Eosinophil Peroxidase; D010544:Peroxidases